Navigation Links
Numira Biosciences Names New Board Member
Date:3/5/2008

Drug discovery and development veteran Paul Grint, M.D. brings extensive

experience to Numira

IRVINE, Calif., March 5 /PRNewswire/ -- Numira Biosciences announced the appointment of Paul Grint, M.D., to its Board of Directors.

Currently, Dr. Grint serves as the Chief Medical Officer and Head of Development at Kalypsys, Inc., a drug discovery and development company based in San Diego, CA. Prior to Kalypsys, he held senior management positions at Zephyr Sciences, Pfizer Global Research & Development, IDEC Pharmaceuticals, and Schering-Plough. Additionally, he is a member of the Board of Directors at Illumina Inc. and serves as Chairman of the Advisory Council of the Keck Graduate Institute.

"We are very pleased to have attracted an industry leader of Dr. Grint's caliber," said Michael Beeuwsaert, President and CEO of Numira. "His extensive background in drug discovery and development will be invaluable to us as we head into our next phase of growth."

About Numira Biosciences

Numira Biosciences is a specialty R&D tools company focused on leveraging advances in genetics and molecular imaging to create a catalog of novel, high-value products that provide researchers with unprecedented insight into genomics, developmental biology, mechanisms of disease, drug efficacy, and toxicity.

For more information, please visit the company's website at http://www.numirabio.com.


'/>"/>
SOURCE Numira Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
4. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
5. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
6. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
7. Anaptys Biosciences Raises Over $33 Million in Series B Financing
8. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
9. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
10. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
11. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 28, 2017 , ... Semrock’s highly popular SearchLight Spectra Viewer ... resource for fluorescence microscopists and optical system designers, enabling The Right Solution, Right ... the globe, SearchLight has become a tremendously popular tool for the fluorescence imaging ...
(Date:4/27/2017)... ... April 27, 2017 , ... Thinksport, the leaders in safe, ... award-winning sunscreen they’ve used the same scientific approach to solving smelly, sweaty athletes, ... the aisles that contain harmful chemicals that should be put nowhere near your ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of its ... times purer and more potent than the market has seen before. Swissx uses proprietary ... well as a patented chromatography process for extraction, to produce its CBD oil--maximizing its ...
(Date:4/26/2017)... , ... April 26, 2017 , ... Journal of ... It can have severe consequences to overall dental health, including complications with speech, eating, ... turn to dental implants to replace lost teeth. As the number of tooth replacements ...
(Date:4/26/2017)... ... April 26, 2017 , ... The ... Excellence upon National Registry of Emergency Medical Technicians and welcomes this ... said Dr. Jan G. West, Ph.D. , CEO & Organizational Psychologist at ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... England , April 24, 2017 ... development, today announced the addition of a major ... ,Validated In-situ Plate Seeding,). The VIPS has been ... and 384 well microplates as part of the ... system offers a simple and more reliable solution ...
(Date:4/20/2017)... 2017 Research and Markets has ... and Market Prospects: Addressing Production Complexities Through Risk Management ... ... Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities Through ... assessment of the current trends in the global biosimilars ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: